RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John D Hainsworth, M.D.
SCRI Development Innovations, LLC
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clearview Cancer Institute
Huntsville, Alabama, United States
- Florida Cancer Specialists
Fort Myers, Florida, United States
- Northeast Georgia Medical Center
Gainesville, Georgia, United States
- Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, United States
- St. Louis Cancer Care
Chesterfield, Missouri, United States
- Research Medical Center
Kansas City, Missouri, United States
- Methodist Cancer Center
Omaha, Nebraska, United States
- South Carolina Oncology Associates, Pa
Columbia, South Carolina, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Peninsula Cancer Institute
Newport News, Virginia, United States
- Virginia Cancer Institute
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2009
- Primary completion
- 31 Oct 2009
- Completion
- 31 May 2013
- Last update posted
- 8 Dec 2021
- Registered enrollment
- 68
- Registry id
- NCT00805961
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.